Parabilis (PBLS) awards director 20,215 options at $20 strike

Rhea-AI Filing Summary

Parabilis Medicines director Barbara Weber received a grant of stock options for 20,215 shares of common stock. The options have an exercise price of $20.00 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the company’s next annual stockholder meeting, subject to her continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Weber Barbara

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,215	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 20,215 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 20,215 options Exercise price: $20.00 per share Expiration date: June 8, 2036 +2 more

5 metrics

Options granted 20,215 options Stock Option (Right to Buy) grant to director

Exercise price $20.00 per share Strike price for the granted options

Expiration date June 8, 2036 Option term end date

Underlying shares 20,215 shares Common stock underlying the options

Post-grant derivative holdings 20,215 options Total options held following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 20.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"The shares underlying this option shall vest and become exercisable in full"

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weber Barbara

(Last) (First) (Middle)

C/O PARABILIS MEDICINES, INC.

30 ACORN PARK DRIVE, 6TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02140

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	06/09/2026		A		20,215		(1)	06/08/2036	Common Stock	20,215	$0	20,215	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Teresa Jurgensen, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Parabilis Medicines (PBLS) report for Barbara Weber?

Parabilis Medicines reported that director Barbara Weber received a grant of 20,215 stock options. These options give her the right to buy common shares at a fixed price, functioning as part of her equity-based compensation package.

What is the exercise price of Barbara Weber’s new Parabilis (PBLS) stock options?

The granted stock options have an exercise price of $20.00 per share. This means she can later buy Parabilis common stock at $20.00, regardless of the market price at the time of exercise.

When do Barbara Weber’s Parabilis (PBLS) stock options vest?

The options vest and become exercisable in full on the earlier of June 9, 2027 or the date of Parabilis’ next annual stockholder meeting. Vesting is conditional on her continued service through that vesting date.

How many Parabilis (PBLS) options does Barbara Weber hold after this grant?

Following this grant, Barbara Weber holds 20,215 stock options directly. Each option is tied to one share of common stock, giving her potential future equity exposure if she exercises them.

Are Barbara Weber’s Parabilis (PBLS) options a market purchase or a compensation award?

The filing classifies the transaction as a grant or award acquisition, not an open-market purchase. She did not pay cash to buy shares; instead, she received options as part of her compensation arrangement.